<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">The European LEMS Registry: Baseline Demographics and Treatment Approaches</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
				<date type="published" when="2015-11-02">November 2, 2015</date>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName><forename type="first">Renato</forename><forename type="middle">Mantegazza</forename><surname>Andreas</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Meisel</forename><surname>Joern</surname></persName>
						</author>
						<author>
							<persName><forename type="first">P</forename><surname>Sieb</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Le</forename><surname>Gwendal</surname></persName>
						</author>
						<author>
							<persName><surname>Masson</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Desnuelle</forename><forename type="middle">Mirko</forename><surname>Claude</surname></persName>
						</author>
						<author>
							<persName><surname>Essing</surname></persName>
						</author>
						<author role="corresp">
							<persName><forename type="first">R</forename><surname>Mantegazza</surname></persName>
							<email>rmantegazza@istituto-besta.it</email>
						</author>
						<author>
							<persName><forename type="first">Istituto</forename><surname>Neurologico</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Carlo</forename><surname>Besta</surname></persName>
						</author>
						<author>
							<persName><roleName>Italy</roleName><surname>Milan</surname></persName>
						</author>
						<author>
							<persName><forename type="first">A</forename><surname>Meisel</surname></persName>
						</author>
						<author>
							<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Sieb</surname></persName>
						</author>
						<author>
							<persName><forename type="first">G</forename><surname>Le Masson</surname></persName>
						</author>
						<author>
							<affiliation key="aff0">
								<orgName type="institution">Charite ´Universita ¨tsmedizin Berlin</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff1">
								<orgName type="institution">Hanse-Klinikum Stralsund</orgName>
								<address>
									<settlement>Stralsund</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff2">
								<orgName type="institution">Ho ˆpital Pellegrin</orgName>
								<address>
									<settlement>Bordeaux</settlement>
									<country>France C</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff3">
								<orgName type="institution">Desnuelle Centre de Re ´fe ´rence Maladies Neuromusculaires-CHU de Nice</orgName>
								<address>
									<settlement>Nice</settlement>
									<country>France M</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff4">
								<orgName type="institution">Essing BioMarin Europe, Ltd</orgName>
								<address>
									<settlement>London</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff5">
								<orgName type="institution">BioMarin Pharmaceutical Inc</orgName>
								<address>
									<settlement>Novato</settlement>
									<region>CA</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">The European LEMS Registry: Baseline Demographics and Treatment Approaches</title>
					</analytic>
					<monogr>
						<imprint>
							<date type="published" when="2015-11-02">November 2, 2015</date>
						</imprint>
					</monogr>
					<idno type="MD5">F4DFF4F6A24DB1160422E9B1DE2D8AAA</idno>
					<idno type="DOI">10.1007/s40120-015-0034-0</idno>
					<note type="submission">Received: July 13, 2015 /</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:14+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>
					<term>3,4-Diaminopyridine (3,4-DAP)</term>
					<term>Amifampridine</term>
					<term>Firdapse</term>
					<term>Lambert-Eaton</term>
					<term>LEMS</term>
					<term>Registry</term>
				</keywords>
			</textClass>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>Introduction: Lambert-Eaton myasthenic syndrome (LEMS) is a rare autoimmune disorder affecting the neuromuscular junction, clinically characterized by proximal muscle weakness and autonomic changes.</s><s>LEMS is</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>often associated with an underlying tumor (paraneoplastic form) but also occurs in the absence of cancer (idiopathic form).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>INTRODUCTION</head><p><s>Lambert-Eaton myasthenic syndrome (LEMS) is a rare autoimmune disorder caused by pathogenic autoantibodies directed against presynaptic voltage-gated Ca v 2.1 (P/Q type) calcium ion channel (VGCC) at the neuromuscular junction (NMJ) <ref type="bibr" target="#b0">[1,</ref><ref type="bibr" target="#b1">2]</ref>.</s><s>It is clinically characterized by limb girdle weakness, increased fatigability, depressed tendon reflexes, and autonomic changes.</s><s>The decreased calcium influx prevents sufficient release of acetylcholine (ACh) from the nerve terminals, subsequent stimulation of the post-synaptic membrane, and attenuates normal muscle contraction <ref type="bibr" target="#b2">[3]</ref><ref type="bibr" target="#b3">[4]</ref><ref type="bibr" target="#b4">[5]</ref>.</s></p><p><s>LEMS is estimated to affect 1:100,000 people in the European community <ref type="bibr" target="#b5">[6]</ref> with an incidence of 0.48 to 0.75 per million <ref type="bibr" target="#b6">[7]</ref>.</s><s>In a study from South Holland, Wirtz et al. <ref type="bibr" target="#b6">[7]</ref> found a LEMS prevalence of 2.3 per million and an annual incidence rate of 0.5 per million.</s><s>The true incidence of LEMS is unknown.</s><s>LEMS is reported to be associated with cancer (paraneoplastic form) in more than 50% of cases, with small cell lung cancer (SCLC) being the most frequently observed associated cancer.</s></p><p><s>The reported percentage of newly diagnosed LEMS cases associated with small SCLC ranges from 40% to 70% <ref type="bibr" target="#b6">[7]</ref><ref type="bibr" target="#b7">[8]</ref><ref type="bibr" target="#b8">[9]</ref>.</s><s>The prevalence of LEMS in patients with SCLC is estimated to be approximately 3% <ref type="bibr" target="#b9">[10]</ref>.</s><s>The low prevalence relative to incidence reflects the poor survival of LEMS patients with the paraneoplastic type of disease, and specifically the poor survival of patients with SCLC.</s><s>The clinical manifestations of LEMS often precede the detection of an underlying carcinoma.</s><s>The associated cancer is usually discovered within the first 2 years after the onset of LEMS and, in almost all cases, within 4 years <ref type="bibr" target="#b10">[11]</ref>.</s><s>LEMS is diagnosed based on the often suggestive clinical presentation, electrophysiological studies, testing for Ca v 2.1 P/Q-type VGCC autoantibodies, and through clinical evaluation (diagnostic considerations are described further in the ''Discussion'').</s></p><p><s>Besides the muscular weakness, LEMS is associated with signs of autonomic dysfunction such as dry mouth, constipation, and erectile dysfunction.</s><s>Activities associated with daily functioning, e.g., climbing stairs without support, rising from a low sitting or squatting position, cycling, are typically affected mildly or moderately <ref type="bibr" target="#b11">[12]</ref>.</s><s>The onset of symptoms, typically at C40 years of age in patients with cancer (median age 60 years), and between 20 and 50 years of age in those without (median age 35 years), is usually gradual and insidious <ref type="bibr" target="#b12">[13]</ref>.</s><s>Rarely, respiratory function may be impaired to the extent of requiring mechanical ventilation.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>LEMS EU Registry: Background and Objectives</head><p><s>The European Federation of Neurological Societies (EFNS) has published guidelines from two different task forces <ref type="bibr" target="#b13">[14]</ref><ref type="bibr" target="#b14">[15]</ref><ref type="bibr" target="#b15">[16]</ref>.</s><s>These guidelines recommend treatment based on consensus assessments of all available evidence, although nearly all of the published empirical evidence consists of disperse case reports and a handful of randomized controlled trials.</s><s>The purpose of the present article is to provide a first interim report on the demographics and clinical characteristics of the accrued patient population at the time of baseline enrollment into the registry.</s><s>Follow-up data for patients will continue to be accrued and will be reported at a later date.</s><s>The registry is sponsored by BioMarin Pharmaceutical Inc.</s></p><p><s>(Novato, CA, USA).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>METHODS</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Registry</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Data Collection and Entry</head><p><s>The registry relies on voluntary submission of data by participating clinical investigators.</s><s>Data from 29 EU centers located in 4 countries: Germany (10 centers), Italy (4 centers), France</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Clinical and Laboratory Assessments</head><p><s>A panel of international clinical experts in the care of patients with LEMS was convened to recommend a set of assessments appropriate for the long-term monitoring of clinical status and outcomes for this patient population (Table <ref type="table" target="#tab_4">1</ref>).</s><s>Although there are very few reports of adverse cardiovascular effects (serious events have been reported in only 2 cases <ref type="bibr" target="#b22">[22,</ref><ref type="bibr" target="#b23">23]</ref> ), 12-lead ECGs are performed to further evaluate and ensure safety.</s><s>The ECG is also specifically evaluated for QT-prolongation and other interval abnormalities (i.e., PR, QTcB, QTcF, QRS).</s></p><p><s>Because of the frequent association of LEMS with SCLC, and published reports have cited involvement of respiratory muscles and the diaphragm in LEMS <ref type="bibr" target="#b24">[24]</ref>, spirometry is recommended periodically if there are concerns about a patient's respiratory functioning or to monitor disease progression.</s></p><p><s>Forced vital capacity (FVC) should be assessed at regular intervals to detect and evaluate the extent of any progressive worsening of muscular weakness.</s><s>PFTs were performed for registry patients according to standard pulmonary testing practices, and percent of predicted values relative to normal subjects were derived, when possible, for key parameters [forced expiratory volume in 1 s (FEV 1 ) and FVC] using published normative data <ref type="bibr" target="#b25">[25]</ref>, taking into account patient's sex, age, and height.</s></p><p><s>Information on health status was obtained periodically using the EuroQoL 5D (EQ-5D), a widely employed health status questionnaire <ref type="bibr" target="#b26">[26]</ref>.</s><s>The EuroQoL 5D assesses an individual's daily functioning via an Investigator's rating of a patient's ability to perform each of 12 activities as either normal/as expected or reduced/limited.</s><s>The evaluation of treatment safety will appear in future reports and will include analyses of adverse events, concomitant medications, and clinical laboratory tests.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Data Analysis</head><p><s>The database used for analysis consisted of all available data for any assessments that were Assessment data are summarized using descriptive methods only using means, standard deviations (SD), medians, quartiles, and ranges (min, max).</s><s>Due to the observational and non-interventional nature of the registry program, no attempts will be made to perform inferential statistical evaluation.</s><s>When statistical data are presented as pooled data, data will be combined from all available patients in the four treatment groups.</s><s>Four patients have been discontinued from the registry.</s><s>Three patients, all who had received 3,4-DAP, were treated as discontinued from the registry due to death.</s><s>Two deaths were the result of cardiac arrest.</s><s>The third death was the result of renal failure followed by multi-organ failure.</s><s>In all 3 cases, death was reported as unrelated to 3,4-DAP and unrelated to other LEMS medications.</s><s>Another patient who had also received 3,4-DAP withdrew from the registry due to moving to another city and has been lost to follow-up.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>RESULTS</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Registry</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Population Demographics and Other</head><p><s>Characteristics</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Diagnostic Characteristics and Clinical</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Status of Patients at Enrollment</head><p><s>The CMAP amplitude parameter assessed during EMG evaluation, along with autoantibody testing (Ca v 2.1 P/Q-type VGCC) and a clinical evaluation of symptoms, were the primary methods used to confirm the diagnosis of LEMS.</s></p><p><s>Results were positive (?ve) at baseline for 19 of the 21 patients for whom VGCC data were available in the overall registry population.</s><s>Associated titers ranged from 32.0 to 735.0 pmol/L (mean 302.9 pmol/L, SD 249.87).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Electrophysiology</head><p><s>The mean percent increment and decrement values and the individual values for the patients for whom EMG testing was available near the time (±1 month) of enrollment into the registry indicated abnormality in neuromuscular functioning for most patients using the standard criteria, i.e., a decrement of [10% and/or a marked increment relative to rest.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Quantitative Myasthenia Gravis</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Questionnaire</head><p><s>Results for the raw QMG Total Score and %Standardized QMG Total Score by treatment group at enrollment are summarized in Table <ref type="table" target="#tab_9">4</ref>.  Electrophysiological testing protocols must be adhered to, however, to achieve consistency and reliability of results across clinical centers.</s></p><p><s>CMAP may be used to periodically monitor the clinical effectiveness of treatment over the long-term.</s><s>Test kits for assay of Ca v 2.1 P/Q-type VGCC autoantibody titers are commercially available.</s></p><p><s>Males and females were equally represented in this study population and there was a wide range of ages at enrollment <ref type="bibr">(27-84 years)</ref>.</s><s>Most patients never smoked or smoked previously but had since quit.</s><s>Review of the overall clinical findings at enrollment presented a picture of generally mild-to-moderate neuromuscular and autonomic impairment for most participants in the registry.</s><s>The majority of patients were assessed as having reduced or limited functioning for activities associated with daily functioning, such as the ability to walk upstairs, cycle, arise from a low chair with and without arm support, arise from sitting on one knee or squatting, and climbing stairs with and without arm support.</s><s>Fewer patients, although still a majority, were assessed as having reduced or limited functioning for the comparatively easier tasks of walking on toes and heels and arise from a high chair with and without arm support.</s><s>These findings are consistent with responses from the EQ-5D health questionnaire which indicated the majority of patients have some problems with mobility and with performing their usual activities.</s><s>tumor (paraneoplastic form), but LEMS can also occur in the absence of cancer (idiopathic form).</s><s>The prevalence of the two forms is similar but the incidence of the paraneoplastic form is much higher <ref type="bibr" target="#b32">[32]</ref>.</s><s>This latter form is most commonly associated with SCLC but can also result from other malignancies <ref type="bibr" target="#b7">[8]</ref>.</s><s>Because only 50-70% of patients with LEMS have an identifiable cancer and because LEMS remains undiagnosed in many cancer patients, the true total prevalence of LEMS may be considerably higher.</s></p><p><s>No consistent pattern of QT interval  <ref type="bibr" target="#b35">[35]</ref>) or its phosphate salt, 3,4-DAP phosphate (amifampridine phosphate, Firdapse).</s><s>However, guanidine is associated with hazardous side effects and its use is limited in clinical practice.</s></p><p><s>The aminopyridines act by blocking voltage-gated potassium channels, thereby prolonging the action potential and increasing calcium ion (Ca 2? ) influx to the nerve terminal.</s><s>Consequently, ACh release is increased, improving neuromuscular transmission and muscle function.</s></p><p><s>Immunomodulating treatment putatively seeks to reduce the tumor antigen-autoantibody response, presumably the lowering of antibody activity directed against Ca v 2.1 P/Q-type VGCCs that mediate ACh release into the NMJ.</s><s>However, even in patients in whom carcinoma has been ruled out, immunosuppression has been shown to have benefit <ref type="bibr" target="#b37">[36]</ref>.</s><s>Immunosuppressive agents such as oral corticosteroids (e.g., prednisolone), azathioprine, MMF, rituximab, or other immunosuppressive agents are frequently employed.</s><s>The objective of therapeutic plasma exchange is to reduce circulating antibody concentrations.</s><s>Although recommended by the National Institute of Health and supported by numerous case reports, no prospective, comparator-controlled evaluations have been published to date.</s><s>Therefore, long-term use is not supported by available data and it is not part of the current guidelines in the clinical neurology practice.</s><s>In the hands of expert physicians, however, it may be safely used.</s></p><p><s>Anticancer treatment is indicated for patients who have the paraneoplastic form of LEMS.</s><s>An algorithm to organize the sequence of each of the above treatment approaches was first proposed in 1998 <ref type="bibr" target="#b38">[37]</ref>, but until recently only little has existed in the way of formalized, evidence-based guidelines.</s><s>This is almost certainly owing to the rarity of the disease and only a gradual accumulation of clinical evidence and a slow evolution in optimizing treatment approaches.</s><s>Several consensus guidelines and review articles on the treatment and management of the neuromuscular transmission disorders, including LEMS, have since emerged in recent years, however.</s></p><p><s>Five randomized, controlled trials consisting of a total of 54 participants with LEMS and who were treated with 3,4-DAP or placebo, and 9 patients who were treated with IVIg or placebo, were identified and included in the review.</s><s>The authors concluded that there was ''…moderate to high-quality evidence from randomised controlled trials that either 3,4-DAP or IVIg</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>CONCLUSIONS</head><p><s>The LEMS EU registry will continue to enroll patients and periodically report on the clinical outcomes of this patient population.</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>(</head><label></label><figDesc><div><p><s>13 centers), and Spain (2 centers) are collected and tabulated.</s><s>Specific clinical and laboratory assessments collected during participation in the registry are further described below.</s><s>Assessment data are continually entered by clinical sites into a centralized registry database via a validated web-portal application.</s><s>Classification and Tracking of LEMS-Specific and LEMS-Related Treatments Treatment information was collected at the time of patient enrollment.</s><s>Due to the observational, non-interventional nature of the LEMS registry, patients may have been newly diagnosed with LEMS at the time of enrollment or may have been previously diagnosed and treated for varying lengths of time.</s><s>Treatment information was organized to reflect that patients could be on different LEMS treatments at different times, both before and/or after the time of enrollment, and all changes in treatments (drug, dose, start/ stop) were made at the discretion of the treating physician and this information was recorded in the registry database.</s><s>LEMS treatments are classified into 1 of 4</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head></head><label></label><figDesc><div><p><s>performed in association with registry enrollment.</s><s>Clinical data were tabulated according to which of the 4 treatments a patient was receiving at the time of consent and enrollment into the registry (Firdapse, 3,4-DAP, Other Treatment, or Unknown Treatment).</s><s>Patients receiving Firdapse at enrollment, either alone or in combination with any other LEMS-specific treatment, were classified into the Firdapse group.</s><s>Similarly, patients receiving 3,4-DAP at enrollment, either alone or in combination with any other LEMS-specific treatment, were classified into the 3,4-DAP group.</s><s>Patients who were not receiving 3,4-DAP or Firdapse at enrollment and who were either known not to be receiving treatment or were not receiving any other LEMS treatment, were classified into the Other Treatments group.</s><s>Patients whose treatment status at enrollment was unknown were classified into the Unknown Treatments group.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_2"><head></head><label></label><figDesc><div><p><s>Population A total of 69 patients have been enrolled into the LEMS registry thus far (Germany n = 30; Spain n = 0; Italy n = 22; France n = 17).</s><s>At time of enrollment, patients were receiving Firdapse (n = 30), 3,4-DAP (n = 15), Other Treatments (n = 16), or Unknown Treatments (n = 8).</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_3"><head>4 -</head><label>4</label><figDesc><div><p><s>DAP 3,4-diaminopyridine, SD standard deviation a SD not computed b Pack-years computed as: [(average number of cigarettes per day/20) 9 number of years smoked] period of between 2 days and up to 14.8 years at the time of enrollment into the registry.</s><s>At least 16 of these patients had been on Firdapse for C1 year prior to registry enrollment.</s><s>Patients were receiving total daily doses of 10-80 mg.</s><s>A total of 40 patients in the registry have received Firdapse at some point, either before, during, and/or after enrollment.</s><s>It is up to the prescribing physician's judgment what the appropriate risk-benefit relationship should be for an individual patient in determining the appropriate dose of Firdapse if it is prescribed outside of the recommended guidelines.</s><s>Fifteen patients were receiving 3,4-DAP base at the time of enrollment with total daily doses of 20-90 mg.</s><s>Most patients had been receiving LEMS-specific or LEMS-related treatment(s) for varying periods of time at the time of enrollment into the registry.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_4"><head>Firdapse</head><label></label><figDesc><div><p><s>Drug classTreatment group (LEMS-specific treatment received at time of enrollment) are expressed in percentage 3,4-DAP 3,4-diaminopyridine, LEMS Lambert-Eaton myasthenic syndrome Counts of treatments are not mutually exclusive; patients could have received a LEMS-specific treatment as a monotherapy or could have received several LEMS-specific treatments as part of combination therapy and/or individually but at different times.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_5"><head></head><label></label><figDesc><div><p><s>The mean %Standardized QMG Total Score at enrollment among the 20 patients in the Firdapse group (19.9, SD 16.0; equivalent to a QMG Total Score of 7.8), 10 patients in the 3,4-DAP group (23.9, SD 25.0; equivalent to a QMG Total Score of 9.3), and the 9 patients of Other LEMS Treatment group (21.2, SD 21.1; equivalent to a QMG Total Score of 8.3) were similar.</s><s>The %Standardized QMG Total Score of the 4 patients receiving Unknown Treatments (11.9 SD, 12.6; equivalent to a QMG Total Score 4.6) was markedly lower than the mean score of the other 3 treatment groups.</s><s>QMG Total Scores</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_6"><head></head><label></label><figDesc><div><p><s>potential amplitudes in people with LEMS.''</s><s>The authors recommended using QMG scores as the primary outcome and change in CMAP as the secondary outcome.A similar report reviewing substantially the same and other data published in 2011<ref type="bibr" target="#b39">[38]</ref> reached essentially equivalent conclusions regarding the use of 3,4-DAP as a first-line symptomatic treatment in combination with long-term immunosuppression, with or without antitumor therapy as indicated.</s><s>The author notes that plasma exchange and short-term use of IVIg have shown acute benefit but are not recommended for long-term, intermittent use.Treatment recommendations from another review<ref type="bibr" target="#b40">[39]</ref> echo virtually the same algorithm of approaches to treatment, i.e., first-line symptomatic treatment with 3,4-DAP/3,4-DAP phosphate, followed by immunosuppressive drug therapy, additional immunomodulation with IVIg, treatment of underlying SCLC if present, and possibly adding on plasma exchange as an acute adjunct.</s><s>QMG symptoms were assessed by standardized protocol [20, 21].</s><s>The mean %Standardized QMG Total Score at enrollment among the 20 patients in the Firdapse group (19.9, SD 16.0; equivalent to a QMG Total Score of 7.8), 10 patients in the 3,4 DAP group (23.9, SD 25.0; equivalent to a QMG Total Score of 9.3), and the 9 patients of Other LEMS Treatment group (21.2, SD 21.1; equivalent to a QMG Total Score of 8.3) were similar.</s><s>The %Standardized QMG Total Score of the 4 patients receiving Unknown Treatments (11.9 SD, 12.6; equivalent to a QMG Total Score 4.6) was markedly lower than the mean score of the other 3 treatment groups.</s><s>QMG Total Scores of [5 (for complete QMG assessments) have been used as a minimum inclusion criteria in clinical studies evaluating the efficacy of 3,4-DAP.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_4"><head>Table 1</head><label>1</label><figDesc><div><p><s>Annual recommended annual clinical assessments for management of Lambert-Eaton myasthenic syndrome</s></p></div></figDesc><table><row><cell cols="5">In addition to their use in establishing an initial</cell></row><row><cell cols="5">diagnosis, the recommended assessments were</cell></row><row><cell cols="5">chosen to monitor changes in LEMS-related</cell></row><row><cell cols="5">clinical manifestations and to stage any disease</cell></row><row><cell cols="5">progression across the life-long course of the</cell></row><row><cell cols="5">disease. Key assessments for LEMS are to</cell></row><row><cell cols="5">periodically obtain: electrophysiological data,</cell></row><row><cell cols="5">quantitative myasthenia gravis (QMG) scores,</cell></row><row><cell cols="5">assessments of muscle strength, testing for</cell></row><row><cell>presence</cell><cell>and</cell><cell>severity</cell><cell>of</cell><cell>ataxia,</cell></row><row><cell cols="5">electrocardiographic (ECG) data (specifically to</cell></row><row><cell cols="5">evaluate QT interval abnormalities), pulmonary</cell></row><row><cell>function</cell><cell>tests</cell><cell>(PFTs),</cell><cell>and</cell><cell>self-report</cell></row><row><cell cols="5">questionnaires on daily functioning and</cell></row><row><cell cols="5">general health status. Each patient's treating</cell></row><row><cell cols="5">physician determined the actual timing and</cell></row><row><cell cols="5">frequency of each assessment according to</cell></row><row><cell cols="3">individualized needs.</cell><cell></cell><cell></cell></row><row><cell cols="5">If the time of initial diagnosis of LEMS did</cell></row><row><cell cols="5">not approximately coincide with the time of</cell></row></table><note><p><s>HR, PQ Interval, PR Interval, QT Interval, QTcB Interval, QTcF Interval, QRS Interval Spirometry 1-s forced expiratory volume (FEV 1 ), forced vital capacity (FVC), total lung capacity (TLC), maximum voluntary ventilation (MVV) Daily functioning Walking ability, cycling, getting up from sitting and squatting, climbing upstairs Health status EuroQol EQ-5D CMAP compound muscle action potential, IgG immunoglobulin G, QMG quantitative myasthenia gravis, VGCC voltage-gated calcium ion channel data to permit improved comparability of mean values and other descriptive statistics between treatment groups.</s><s>In these cases, each patient's raw QMG Total Score is standardized on the basis of the number of sub-scales for which assessment data are available: %Standardized QMG Total Score = [raw QMG Total Score/(N of sub-scales with available data 9 maximum sub-scale score of 3)].</s><s>The %Standardized QMG Total Score is interpreted for the purposes of this registry as the percent of the maximum possible Total QMG Score of 39 when a complete assessment has been performed (e.g., a %Standardized QMG Total Score of 0.66 or 66% implies that a patient's Total QMG Score was equivalent to 26 on a complete QMG assessment).</s><s>Patients' muscle strength is assessed in 13 muscles or muscle groups: biceps, triceps, wrist flexion, wrist extension, hamstring, quadriceps, foot flexor, foot extensor, iliopsoas, gluteus maximus, neck flexor, neck extensor, and facial muscles.</s><s>Muscle strength is rated on a 5-point scale for each muscle group, ranging from 0 (absent voluntary contraction) to 5 (full strength).</s><s>The strength of facial muscles is rated as: 1 (normal), 2 (abnormal), or 3 (not done).</s><s>Deep tendon reflexes are assessed at the knee, Achilles, biceps, and triceps.</s><s>Ataxia is assessed from a line walk test, Romberg's test, and finger-to-nose and heel-to-knee tests.</s><s>Any signs of autonomic dysfunction are recorded (i.e., dry eyes or mouth, abnormal pupil reflexes, constipation, bladder dysfunction, erectile dysfunction/impotence, orthostatic intolerance).</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_5"><head>Table 2</head><label>2</label><figDesc></figDesc><table><row><cell cols="3">summarizes patient demographics and</cell></row><row><cell cols="3">other characteristics by treatment group (data</cell></row><row><cell cols="3">were not available for one enrolled patient). The</cell></row><row><cell cols="3">mean age at time of enrollment is 61.5 years (SD</cell></row><row><cell cols="3">11.9 years, range 27-84 years). There are several</cell></row><row><cell cols="3">more males (36/69; 52.2%) than females (32/69;</cell></row><row><cell cols="3">46.4%) and the majority of patients are</cell></row><row><cell cols="3">Caucasian (51/69; 73.9%). Information on</cell></row><row><cell cols="3">ethnicity was not available from patients</cell></row><row><cell cols="3">enrolled at centers in France due to national</cell></row><row><cell cols="3">reporting restrictions prohibiting the collection</cell></row><row><cell cols="3">of ethnicity data. Most patients either never</cell></row><row><cell cols="3">smoked (32/69; 46.4%) or smoked previously but</cell></row><row><cell cols="3">have since quit (25/69; 36.2%), and 10 patients</cell></row><row><cell cols="3">(14.5%) are current smokers. Two patients have</cell></row><row><cell cols="3">unreported information on smoking history.</cell></row><row><cell cols="3">Results for Ca v 2.1 P/Q-type VGCC antibody</cell></row><row><cell cols="3">assays were positive (?ve) for 19 of the 21</cell></row><row><cell cols="3">patients for whom VGCC data were available in</cell></row><row><cell cols="3">the overall registry population, with associated</cell></row><row><cell cols="3">titers ranging from 32.0 to 735.0 pmol per liter</cell></row><row><cell cols="3">(pmol/L) (mean 302.9 pmol/L, SD 249.87;</cell></row><row><cell cols="2">normal range \20 pmol/L [27]).</cell><cell></cell></row><row><cell cols="3">At the time of enrollment, the majority of</cell></row><row><cell cols="3">patients were receiving either Firdapse (30/69;</cell></row><row><cell cols="3">43.5%) or 3,4-DAP (15/69; 21.7%). Eleven</cell></row><row><cell cols="3">patients were diagnosed with lung cancer</cell></row><row><cell>(Firdapse = 4,</cell><cell>3,4-DAP = 2,</cell><cell>Unknown</cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_6"><head>Table 2</head><label>2</label><figDesc><div><p><s>Registry population demographics and baseline characteristics</s></p></div></figDesc><table><row><cell>Characteristic</cell><cell cols="4">Treatment group (treatment received at time of enrollment)</cell><cell>Total (N 5 69)</cell></row><row><cell></cell><cell cols="4">Firdapse (n 5 30) 3,4-DAP (n 5 15) Other (n 5 16) Unknown (n 5 8)</cell><cell></cell></row><row><cell cols="2">Age at time of informed consent (years)</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>n</cell><cell>30</cell><cell>15</cell><cell>16</cell><cell>6</cell><cell>67</cell></row><row><cell>Mean (SD)</cell><cell>60.5 (10.1)</cell><cell>64.5 (12.4)</cell><cell>63.7 (11.9)</cell><cell>52.8 (16.7)</cell><cell>61.5 (11.9)</cell></row><row><cell>Min-max</cell><cell>38.0-77.0</cell><cell>38.0-84.0</cell><cell>34.0-76.0</cell><cell>27.0-74.0</cell><cell>27.0-84.0</cell></row><row><cell>Gender, n (%)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Male</cell><cell>16 (53.3)</cell><cell>7 (46.7)</cell><cell>8 (50.0)</cell><cell>5 (62.5)</cell><cell>36 (52.2)</cell></row><row><cell>Female</cell><cell>14 (46.7)</cell><cell>8 (53.3)</cell><cell>8 (50.0)</cell><cell>2 (25.0)</cell><cell>32 (46.4)</cell></row><row><cell>Unreported</cell><cell></cell><cell></cell><cell></cell><cell>1 (12.5)</cell><cell>1 (1.4)</cell></row><row><cell cols="2">Smoking history, n (%)</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Current smoker</cell><cell>6 (20.0)</cell><cell>0 (0.0)</cell><cell>3 (18.8)</cell><cell>1 (12.5)</cell><cell>10 (14.5)</cell></row><row><cell cols="2">Smoked previously 12 (40.0)</cell><cell>2 (13.3)</cell><cell>6 (37.5)</cell><cell>5 (62.5)</cell><cell>25 (36.2)</cell></row><row><cell>Never smoked</cell><cell>12 (40.0)</cell><cell>13 (86.7)</cell><cell>6 (37.5)</cell><cell>1 (12.5)</cell><cell>32 (46.4)</cell></row><row><cell>Unreported</cell><cell></cell><cell></cell><cell>1 (6.3)</cell><cell>1 (12.5)</cell><cell>2 (2.9)</cell></row><row><cell cols="2">Pack-years for current smokers b</cell><cell></cell><cell></cell><cell></cell><cell></cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_7"><head>Table 3 summarizes</head><label>3</label><figDesc><div><p><s>LEMS-specific treatments other than Firdapse or 3,4-DAP base that were received at any time (i.e., received prior to or after registry enrollment) by treatment group.</s></p></div></figDesc><table><row><cell cols="3">There were no other LEMS-specific treatments</cell></row><row><cell cols="3">received by patients in the Unknown LEMS</cell></row><row><cell cols="3">treatments group. Besides Firdapse or 3,4-DAP,</cell></row><row><cell>immunomodulators,</cell><cell>most</cell><cell>commonly</cell></row><row><cell cols="3">immunosuppressants, were the most frequently</cell></row><row><cell cols="3">employed LEMS-specific treatment: 12 patients</cell></row><row><cell cols="3">received azathioprine, 2 patients received</cell></row><row><cell>cyclophosphamide,</cell><cell>4 patients</cell><cell>received</cell></row><row><cell cols="3">mycophenolate mofetil (MMF), 2 patients</cell></row><row><cell cols="3">received cyclosporine A, 19 patients received</cell></row><row><cell>prednisone,</cell><cell>1 patient</cell><cell>received</cell></row><row><cell cols="3">methylprednisolone, and 10 patients received</cell></row><row><cell cols="3">IVIg therapy. Twenty-two patients received</cell></row><row><cell>pyridostigmine.</cell><cell></cell><cell></cell></row><row><cell cols="3">Twenty-six patients (37.7%; 26/69) had only</cell></row><row><cell cols="3">ever received monotherapy, consisting of</cell></row><row><cell cols="3">Firdapse (17.4%; 12/69), 3,4-DAP base (13.0%;</cell></row><row><cell cols="3">9/69), pyridostigmine (2.9%; 2/69), prednisone</cell></row><row><cell cols="3">(2.9%; 2/69), and normal immunoglobulin</cell></row><row><cell cols="3">(1.4%; 1/69). The remaining patients (62.3%;</cell></row><row><cell cols="3">43/69) were on LEMS polytherapy treatments</cell></row><row><cell cols="3">consisting of any combination of LEMS</cell></row><row><cell cols="3">medications, received either concomitantly</cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_8"><head>Table 3</head><label>3</label><figDesc><div><p><s>LEMS-specific treatments administered at any time, by drug class and registry treatment group</s></p></div></figDesc><table /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_9"><head>Table 4</head><label>4</label><figDesc><div><p><s>QMG assessment: mean QMG Total Score and %Standardized QMG Total Score</s></p></div></figDesc><table><row><cell>Assessment</cell><cell cols="5">Firdapse (n 5 30) 3,4-DAP (n 5 15) Other (n 5 16) Unknown (n 5 8) Total (N 5 69)</cell></row><row><cell cols="2">QMG Total Score</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>n</cell><cell>21</cell><cell>10</cell><cell>9</cell><cell>4</cell><cell>44</cell></row><row><cell cols="2">Mean (SD) 7.4 (6.3)</cell><cell>9.1 (9.7)</cell><cell>5.7 (4.7)</cell><cell>4.5 (4.8)</cell><cell>7.2 (6.8)</cell></row><row><cell>Min-max</cell><cell>0.0-22.0</cell><cell>0.0-26.0</cell><cell>0.0-13.0</cell><cell>0.0-10.0</cell><cell>0.0-26.0</cell></row><row><cell cols="2">%Standardized Total QMG Score a</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>n</cell><cell>20</cell><cell>10</cell><cell>9</cell><cell>4</cell><cell>43</cell></row><row><cell cols="2">Mean (SD) 19.9 (16.0)</cell><cell>23.9 (25.0)</cell><cell>21.2 (21.1)</cell><cell>11.9 (12.6)</cell><cell>20.4 (18.8)</cell></row><row><cell>Min-max</cell><cell>0.0-56.4</cell><cell>0.0-66.7</cell><cell>0.0-66.7</cell><cell>0.0-25.6</cell><cell>0.0-66.7</cell></row></table><note><p><s>3,4-DAP 3,4 diaminopyridine, QMG quantitative myasthenia gravis, SD standard deviation a %Standardized Total QMG Score computed as: [raw QMG Total Score/(N of sub-scales with available data 9 maximum sub-scale score of 3)]</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_12"><head></head><label></label><figDesc><div><p><s>The Advisory Board, and as a Consultants to BioMarin Europe Ltd.</s><s>Gwendal Le Masson has received financial compensation for his participation as an Investigator in the LEMS Registry, as a member of the LEMS Registry Advisory Board, and as a Consultants to BioMarin Europe Ltd.</s><s>Claude Desnuelle has received financial compensation for his participation as an Investigator in the LEMS Registry, as a member of the LEMS Registry Advisory Board, and as a Consultants to BioMarin Europe Ltd.</s><s>Mirko Essing is an employee of BioMarin Europe Ltd.</s><s>Compliance with ethics guidelines.</s><s>All registry procedures that were and are being conducted in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964, as revised in 2013.</s><s>Informed consent was obtained from all patients included in the study.</s><s>The LEMS registry protocol, patient information sheet, and informed consent form have been submitted to and approved by an ethics committee (EC), subject to applicable local laws at each center where the registry is being conducted.</s><s>In countries participating in the LEMS registry where approvals other than an EC approval were required, all applicable requirements were met and approved.</s><s>Applicable approvals were completed and in place prior to site initiation and patient enrollment.</s><s>All documents are on file at the registry's Sponsor, BioMarin Europe Ltd.</s><s>(London, UK).</s><s>Open Access.</s><s>This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/ by-nc/4.0/),</s><s>which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.</s></p></div></figDesc><table /></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">Neurol Ther (2015) 4:105-124</note>
		</body>
		<back>
			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>findings of this registry will contribute to a better understanding of LEMS and its natural history, as well as the diagnostic and therapeutic challenges facing patients and the healthcare professionals who care for them.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>ACKNOWLEDGMENTS</head></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">Voltage gated calcium channel antibody-related neurological diseases</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">E</forename><surname>Bekircan-Kurt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">D</forename><surname>Kurne</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">T</forename><surname>Anlar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">World J Clin Cases</title>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="293" to="300" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">Calcium channels-basic aspects of their structure, function and gene encoding; anesthetic action on the channels-a review</title>
		<author>
			<persName><forename type="first">M</forename><surname>Yamakage</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Namiki</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Can J Anesth</title>
		<imprint>
			<biblScope unit="volume">49</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="151" to="164" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Calcium-channel antibodies in the Lambert-Eaton Syndrome and other paraneoplastic syndromes</title>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">A</forename><surname>Lennon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">J</forename><surname>Kryzer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">E</forename><surname>Griesmann</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">332</biblScope>
			<biblScope unit="page" from="1467" to="1474" />
			<date type="published" when="1995">1995</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Eaton myasthenic syndrome</title>
		<author>
			<persName><forename type="first">U</forename><surname>Seneviratne</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Silva</forename><forename type="middle">R</forename><surname>De</surname></persName>
		</author>
		<author>
			<persName><surname>Lambert</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Postgrad Med J</title>
		<imprint>
			<biblScope unit="volume">75</biblScope>
			<biblScope unit="page" from="516" to="520" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Eaton myasthenic syndrome</title>
		<author>
			<persName><forename type="first">Davis</forename><forename type="middle">J</forename><surname>Newsom-</surname></persName>
		</author>
		<author>
			<persName><surname>Lambert</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Rev Neurol (Paris)</title>
		<imprint>
			<biblScope unit="volume">160</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="177" to="180" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<monogr>
		<title level="m" type="main">Lambert-Eaton myasthenic syndrome</title>
		<author>
			<persName><forename type="first">M</forename><surname>Titulaer</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
	<note>Internet. updated 2013 November</note>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">The epidemiology of myasthenia gravis, Lambert-Eaton myasthenic syndrome and their associated tumours in the northern part of the province of South Holland</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">W</forename><surname>Wirtz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">G</forename><surname>Nijnuis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Sotodeh</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Neurol</title>
		<imprint>
			<biblScope unit="volume">250</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="698" to="701" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">The Lambert-Eaton Myasthenic syndrome. A review of 50 cases</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">H</forename><surname>O'neill</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Nmf</forename><surname>Murray</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Newsom-Davis</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Brain</title>
		<imprint>
			<biblScope unit="volume">111</biblScope>
			<biblScope unit="page" from="577" to="596" />
			<date type="published" when="1988">1988</date>
		</imprint>
	</monogr>
	<note>Pt.3</note>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Trends in the association of Lambert-Eaton myasthenic syndrome with carcinoma</title>
		<author>
			<persName><forename type="first">L</forename><surname>Gutmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">H</forename><surname>Phillips</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Gutmann</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neurology</title>
		<imprint>
			<biblScope unit="volume">42</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="848" to="850" />
			<date type="published" when="1992">1992</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Prospective study into the incidence of Lambert Eaton myasthenic syndrome in small cell lung cancer</title>
		<author>
			<persName><forename type="first">M</forename><surname>Payne</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Bradbury</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Lang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Thorac Oncol</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="34" to="38" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title/>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">E</forename><surname>Stickler</surname></persName>
		</author>
		<author>
			<persName><surname>Lambert-Eaton Myasthenic Sydrome</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="s">LEMS</title>
		<imprint>
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
	<note>Internet. updated 2013 May3</note>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Long-term disease history, clinical symptoms, health status, and healthcare utilization in patients suffering from Lambert Eaton myasthenic syndrome: results of a patient interview survey in Germany</title>
		<author>
			<persName><forename type="first">L</forename><surname>Harms</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Peter</forename><surname>Sieb</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J-P</forename><surname>Williams</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">E</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Med Econ</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="521" to="530" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">Eaton myasthenic syndrome: diagnosis and treatment</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">B</forename><surname>Sanders</surname></persName>
		</author>
		<author>
			<persName><surname>Lambert</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann N Y Acad Sci</title>
		<imprint>
			<biblScope unit="volume">998</biblScope>
			<biblScope unit="page" from="500" to="508" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Management of paraneoplastic neurological syndromes: report of an EFNS Task Force</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">A</forename><surname>Vedeler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Antoine</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Giometto</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Neurol</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page" from="682" to="690" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Guidelines for treatment of autoimmune neuromuscular transmission disorders</title>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">O</forename><surname>Skeie</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Apostolskib</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Evolic</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Neurol</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="page" from="893" to="902" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Paraneoplastic neurological syndromes</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">A</forename><surname>Vedeler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Antoine</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Giometto</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">European handbook of neurological management</title>
				<editor>
			<persName><forename type="first">N</forename><forename type="middle">E</forename><surname>Gilhus</surname></persName>
		</editor>
		<editor>
			<persName><forename type="first">M</forename><forename type="middle">P</forename><surname>Barnes</surname></persName>
		</editor>
		<editor>
			<persName><forename type="first">M</forename><surname>Brainin</surname></persName>
		</editor>
		<meeting><address><addrLine>Oxford (UK</addrLine></address></meeting>
		<imprint>
			<publisher>Wiley-Blackwell</publisher>
			<date type="published" when="2011">2011</date>
			<biblScope unit="volume">1</biblScope>
		</imprint>
	</monogr>
	<note>2nd ed</note>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Literature review of the usefulness of repetitive nerve stimulation and single fiber EMG in the electrodiagnostic evaluation of patients with suspected myasthenia gravis or Lambert-Eaton myasthenic syndrome</title>
	</analytic>
	<monogr>
		<title level="j">Muscle Nerve</title>
		<imprint>
			<biblScope unit="volume">24</biblScope>
			<biblScope unit="issue">9</biblScope>
			<biblScope unit="page" from="1239" to="1247" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Practice parameter for repetitive nerve stimulation and single fiber EMG evaluation of adults with suspected myasthenia gravis or Lambert-Eaton myasthenic syndrome: summary statement</title>
	</analytic>
	<monogr>
		<title level="m">AAEM Quality Assurance Committee</title>
				<imprint>
			<date type="published" when="2001">2001</date>
			<biblScope unit="volume">24</biblScope>
			<biblScope unit="page" from="1236" to="1238" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">Efficacy of 3,4 diaminopyridine and pyridostigmine in the treatment of Lambert-Eaton myasthenic syndrome: a randomized double-blind placebo controlled cross over study</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">W</forename><surname>Wirtz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">J</forename><surname>Verschuren</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">G</forename><surname>Van Dijk</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Pharmacol Ther</title>
		<imprint>
			<biblScope unit="volume">86</biblScope>
			<biblScope unit="page" from="44" to="48" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<monogr>
		<title level="m" type="main">Reliability testing of the quantitative myasthenia gravis score</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">J</forename><surname>Barohn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Mcintire</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Herbelin</surname></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title/>
	</analytic>
	<monogr>
		<title level="j">Ann N Y Acad Sci</title>
		<imprint>
			<biblScope unit="volume">841</biblScope>
			<biblScope unit="page" from="769" to="772" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">Lambert-Eaton myasthenic syndrome</title>
		<author>
			<persName><forename type="first">C</forename><surname>Jablecki</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Muscle Nerve</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="250" to="257" />
			<date type="published" when="1984">1984</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">Cardiac arrest following a iatrogenic by 3,4-diaminopyridine intoxication in a patient with Lambert-Eaton myasthenic syndrome</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">E</forename><surname>Boerma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">H</forename><surname>Rommes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">B</forename><surname>Van Leeuwen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Bakker</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Toxicol Clin Toxicol</title>
		<imprint>
			<biblScope unit="volume">33</biblScope>
			<biblScope unit="page" from="249" to="251" />
			<date type="published" when="1995">1995</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">Practical aspects of 3,4-diaminopyridine treatment of the Lambert-Eaton myasthenic syndrome</title>
		<author>
			<persName><forename type="first">H</forename><surname>Lundh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Nilsson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Rosen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Johansson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Acta Neurol Scand</title>
		<imprint>
			<biblScope unit="volume">88</biblScope>
			<biblScope unit="page" from="136" to="140" />
			<date type="published" when="1993">1993</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">Lambert-Eaton myasthenic syndrome involving the diaphragm</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">G</forename><surname>Wilcox</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">J</forename><surname>Morrison</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">R</forename><surname>Anzarut</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">L</forename><surname>Pardy</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Chest</title>
		<imprint>
			<biblScope unit="volume">93</biblScope>
			<biblScope unit="page" from="604" to="606" />
			<date type="published" when="1988">1988</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">Spirometric reference values from a sample of the general US population</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Hankinson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">R</forename><surname>Odencrantz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">B</forename><surname>Fedan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Respir Crit Care Med</title>
		<imprint>
			<biblScope unit="volume">159</biblScope>
			<biblScope unit="page" from="179" to="187" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<monogr>
		<title level="m" type="main">EuroQol-a new facility for the measurement of health-related quality of life. Health Policy</title>
		<imprint>
			<date type="published" when="1990">1990</date>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="page" from="199" to="208" />
		</imprint>
		<respStmt>
			<orgName>The EuroQol Group</orgName>
		</respStmt>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">An improved diagnostic assay for Lambert-Eaton myasthenic syndrome</title>
		<author>
			<persName><forename type="first">M</forename><surname>Motomura</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Johnston</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Lang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Vincent</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Newsom-Davis</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Neurol Neurosurg Psychiatry</title>
		<imprint>
			<biblScope unit="volume">58</biblScope>
			<biblScope unit="page" from="85" to="87" />
			<date type="published" when="1995">1995</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">A randomized trial of 3,4-diaminopyridine in Lambert-Eaton myasthenic syndrome</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">B</forename><surname>Sanders</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Massey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">L</forename><surname>Sanders</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">J</forename><surname>Edwards</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neurology</title>
		<imprint>
			<biblScope unit="volume">54</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="603" to="607" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">Lambert-Eaton myasthenic syndrome</title>
		<author>
			<persName><forename type="first">M</forename><surname>Mareska</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Gutmann</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Semin Neurol</title>
		<imprint>
			<biblScope unit="volume">24</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="149" to="153" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">Paraneoplastic cerebellar degeneration. III. Cerebellar degeneration, cancer, and the Lambert-Eaton myasthenic syndrome</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">D</forename><surname>Clouston</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">B</forename><surname>Saper</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Arbizu</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neurology</title>
		<imprint>
			<biblScope unit="volume">42</biblScope>
			<biblScope unit="page" from="1944" to="1950" />
			<date type="published" when="1992">1992</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main">Understanding the physiopathology of paraneoplastic and genetic cerebellar ataxia</title>
		<author>
			<persName><forename type="first">J</forename><surname>Honnorat</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Neurol Neurosurg Psychiatry</title>
		<imprint>
			<biblScope unit="volume">77</biblScope>
			<biblScope unit="issue">12</biblScope>
			<biblScope unit="page" from="1299" to="1300" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main">Therapy in myasthenia gravis and Lambert-Eaton myasthenic syndrome</title>
		<author>
			<persName><forename type="first">J</forename><surname>Newsom-Davis</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Semin Neurol</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="191" to="198" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main">Content variability of active drug substance in compounded oral 3,4-diaminopyridine products</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">M</forename><surname>Green</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">C</forename><surname>Jones</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">R</forename><surname>Brain</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Pharm Ther</title>
		<imprint>
			<biblScope unit="volume">37</biblScope>
			<biblScope unit="page" from="53" to="57" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title/>
	</analytic>
	<monogr>
		<title level="j">Ann N Y Acad Sci</title>
		<imprint>
			<biblScope unit="volume">135</biblScope>
			<biblScope unit="page" from="367" to="384" />
			<date type="published" when="1966">1966</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b35">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">M</forename><surname>Mcevoy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Windebank</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">R</forename><surname>Daube</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">A</forename><surname>Low</surname></persName>
		</author>
		<imprint/>
	</monogr>
	<note>3,4-Diaminopyridine in the treatment of</note>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title level="a" type="main">Eaton myasthenic syndrome</title>
		<author>
			<persName><surname>Lambert</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">321</biblScope>
			<biblScope unit="issue">23</biblScope>
			<biblScope unit="page" from="1567" to="1571" />
			<date type="published" when="1989">1989</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b37">
	<analytic>
		<title level="a" type="main">Long term outcome in Lambert-Eaton myasthenic syndrome without lung cancer</title>
		<author>
			<persName><forename type="first">P</forename><surname>Maddison</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Lang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Mills</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Newsom-Davis</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Neurol Neurosurg Psychiatry</title>
		<imprint>
			<biblScope unit="volume">70</biblScope>
			<biblScope unit="page" from="212" to="217" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b38">
	<analytic>
		<title level="a" type="main">A treatment algorithm for Lambert-Eaton myasthenic syndrome</title>
		<author>
			<persName><forename type="first">J</forename><surname>Newsom-Davis</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann N Y Acad Sci</title>
		<imprint>
			<biblScope unit="volume">841</biblScope>
			<biblScope unit="page" from="817" to="822" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b39">
	<analytic>
		<title level="a" type="main">Treatment of Lambert-Eaton myasthenic syndrome</title>
		<author>
			<persName><forename type="first">P</forename><surname>Maddison</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann N Y Acad</title>
		<imprint>
			<biblScope unit="volume">1275</biblScope>
			<biblScope unit="page" from="78" to="84" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b40">
	<monogr>
		<title level="m" type="main">Eaton myasthenic syndrome</title>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">E</forename><surname>Gilhus</surname></persName>
		</author>
		<author>
			<persName><surname>Lambert</surname></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b41">
	<analytic>
		<title/>
		<idno type="DOI">10.4061/2011/973808</idno>
	</analytic>
	<monogr>
		<title level="j">Autoimmune Dis</title>
		<imprint>
			<biblScope unit="volume">2011</biblScope>
			<biblScope unit="page" from="1" to="5" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
	<note>pathogenesis</note>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
